nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirtazapine—HRH1—atherosclerosis	0.427	1	CbGaD
Mirtazapine—CYP2C8—Simvastatin—atherosclerosis	0.0283	0.0949	CbGbCtD
Mirtazapine—CYP2C8—Pravastatin—atherosclerosis	0.0277	0.0929	CbGbCtD
Mirtazapine—CYP2C8—Lovastatin—atherosclerosis	0.0277	0.0929	CbGbCtD
Mirtazapine—CYP2D6—Niacin—atherosclerosis	0.0228	0.0766	CbGbCtD
Mirtazapine—CYP2C9—Rosuvastatin—atherosclerosis	0.0212	0.0712	CbGbCtD
Mirtazapine—CYP2C9—Simvastatin—atherosclerosis	0.0197	0.0662	CbGbCtD
Mirtazapine—CYP2C9—Lovastatin—atherosclerosis	0.0193	0.0648	CbGbCtD
Mirtazapine—CYP2C9—Pravastatin—atherosclerosis	0.0193	0.0648	CbGbCtD
Mirtazapine—CYP2D6—Simvastatin—atherosclerosis	0.0181	0.0605	CbGbCtD
Mirtazapine—CYP2D6—Lovastatin—atherosclerosis	0.0177	0.0592	CbGbCtD
Mirtazapine—CYP2D6—Pravastatin—atherosclerosis	0.0177	0.0592	CbGbCtD
Mirtazapine—CYP3A4—Rosuvastatin—atherosclerosis	0.0124	0.0414	CbGbCtD
Mirtazapine—CYP3A4—Ezetimibe—atherosclerosis	0.0124	0.0414	CbGbCtD
Mirtazapine—CYP3A4—Simvastatin—atherosclerosis	0.0115	0.0385	CbGbCtD
Mirtazapine—CYP3A4—Pravastatin—atherosclerosis	0.0112	0.0377	CbGbCtD
Mirtazapine—CYP3A4—Lovastatin—atherosclerosis	0.0112	0.0377	CbGbCtD
Mirtazapine—HTR2A—arteriole—atherosclerosis	0.00208	0.128	CbGeAlD
Mirtazapine—HTR7—vein—atherosclerosis	0.00199	0.122	CbGeAlD
Mirtazapine—Phenindamine—HRH1—atherosclerosis	0.00138	0.254	CrCbGaD
Mirtazapine—HTR2A—vein—atherosclerosis	0.00124	0.0763	CbGeAlD
Mirtazapine—Azatadine—HRH1—atherosclerosis	0.00108	0.198	CrCbGaD
Mirtazapine—Chlorcyclizine—HRH1—atherosclerosis	0.00106	0.195	CrCbGaD
Mirtazapine—Methdilazine—HRH1—atherosclerosis	0.000934	0.172	CrCbGaD
Mirtazapine—HTR2A—hindlimb—atherosclerosis	0.000824	0.0507	CbGeAlD
Mirtazapine—HTR7—artery—atherosclerosis	0.00081	0.0498	CbGeAlD
Mirtazapine—HTR2A—appendage—atherosclerosis	0.000707	0.0435	CbGeAlD
Mirtazapine—HTR7—endothelium—atherosclerosis	0.000684	0.0421	CbGeAlD
Mirtazapine—HTR7—blood vessel—atherosclerosis	0.000631	0.0388	CbGeAlD
Mirtazapine—Epinastine—HRH1—atherosclerosis	0.000624	0.115	CrCbGaD
Mirtazapine—HTR2A—artery—atherosclerosis	0.000505	0.0311	CbGeAlD
Mirtazapine—HTR2A—endothelium—atherosclerosis	0.000427	0.0262	CbGeAlD
Mirtazapine—ADRB1—connective tissue—atherosclerosis	0.000395	0.0243	CbGeAlD
Mirtazapine—HTR2A—blood vessel—atherosclerosis	0.000394	0.0242	CbGeAlD
Mirtazapine—Mianserin—HRH1—atherosclerosis	0.000361	0.0663	CrCbGaD
Mirtazapine—ADRB1—cardiovascular system—atherosclerosis	0.000343	0.0211	CbGeAlD
Mirtazapine—HTR2B—cardiovascular system—atherosclerosis	0.000329	0.0202	CbGeAlD
Mirtazapine—HTR7—connective tissue—atherosclerosis	0.000324	0.0199	CbGeAlD
Mirtazapine—ADRB1—adipose tissue—atherosclerosis	0.000303	0.0186	CbGeAlD
Mirtazapine—HTR1A—cardiovascular system—atherosclerosis	0.000295	0.0181	CbGeAlD
Mirtazapine—HTR2B—adipose tissue—atherosclerosis	0.00029	0.0178	CbGeAlD
Mirtazapine—Back pain—Ezetimibe—atherosclerosis	0.000286	0.002	CcSEcCtD
Mirtazapine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000285	0.00199	CcSEcCtD
Mirtazapine—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000284	0.00199	CcSEcCtD
Mirtazapine—Mental disorder—Simvastatin—atherosclerosis	0.000284	0.00199	CcSEcCtD
Mirtazapine—Tremor—Lovastatin—atherosclerosis	0.000282	0.00198	CcSEcCtD
Mirtazapine—HTR7—cardiovascular system—atherosclerosis	0.000282	0.0173	CbGeAlD
Mirtazapine—Ill-defined disorder—Lovastatin—atherosclerosis	0.00028	0.00196	CcSEcCtD
Mirtazapine—Eye disorder—Niacin—atherosclerosis	0.000278	0.00195	CcSEcCtD
Mirtazapine—Flatulence—Simvastatin—atherosclerosis	0.000278	0.00194	CcSEcCtD
Mirtazapine—Tinnitus—Niacin—atherosclerosis	0.000277	0.00194	CcSEcCtD
Mirtazapine—Erythema multiforme—Pravastatin—atherosclerosis	0.000277	0.00194	CcSEcCtD
Mirtazapine—Dysgeusia—Simvastatin—atherosclerosis	0.000276	0.00193	CcSEcCtD
Mirtazapine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000274	0.00192	CcSEcCtD
Mirtazapine—Anaemia—Ezetimibe—atherosclerosis	0.000273	0.00191	CcSEcCtD
Mirtazapine—Tinnitus—Pravastatin—atherosclerosis	0.000273	0.00191	CcSEcCtD
Mirtazapine—Malaise—Lovastatin—atherosclerosis	0.000272	0.0019	CcSEcCtD
Mirtazapine—Cardiac disorder—Pravastatin—atherosclerosis	0.000272	0.0019	CcSEcCtD
Mirtazapine—ADRA1A—cardiovascular system—atherosclerosis	0.000272	0.0167	CbGeAlD
Mirtazapine—Vertigo—Lovastatin—atherosclerosis	0.000271	0.0019	CcSEcCtD
Mirtazapine—Angiopathy—Niacin—atherosclerosis	0.00027	0.00189	CcSEcCtD
Mirtazapine—Leukopenia—Lovastatin—atherosclerosis	0.00027	0.00189	CcSEcCtD
Mirtazapine—Chills—Niacin—atherosclerosis	0.000267	0.00187	CcSEcCtD
Mirtazapine—Malaise—Ezetimibe—atherosclerosis	0.000267	0.00187	CcSEcCtD
Mirtazapine—Arrhythmia—Niacin—atherosclerosis	0.000266	0.00186	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000264	0.00185	CcSEcCtD
Mirtazapine—Tremor—Simvastatin—atherosclerosis	0.000264	0.00185	CcSEcCtD
Mirtazapine—Alopecia—Niacin—atherosclerosis	0.000263	0.00184	CcSEcCtD
Mirtazapine—Chills—Pravastatin—atherosclerosis	0.000263	0.00184	CcSEcCtD
Mirtazapine—Insomnia—Rosuvastatin—atherosclerosis	0.000262	0.00184	CcSEcCtD
Mirtazapine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000262	0.00183	CcSEcCtD
Mirtazapine—Arrhythmia—Pravastatin—atherosclerosis	0.000262	0.00183	CcSEcCtD
Mirtazapine—Palpitations—Ezetimibe—atherosclerosis	0.000261	0.00183	CcSEcCtD
Mirtazapine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000261	0.00182	CcSEcCtD
Mirtazapine—Anaemia—Simvastatin—atherosclerosis	0.000261	0.00182	CcSEcCtD
Mirtazapine—Malnutrition—Niacin—atherosclerosis	0.000259	0.00181	CcSEcCtD
Mirtazapine—Alopecia—Pravastatin—atherosclerosis	0.000259	0.00181	CcSEcCtD
Mirtazapine—Cough—Ezetimibe—atherosclerosis	0.000258	0.00181	CcSEcCtD
Mirtazapine—Myalgia—Lovastatin—atherosclerosis	0.000257	0.0018	CcSEcCtD
Mirtazapine—Arthralgia—Lovastatin—atherosclerosis	0.000257	0.0018	CcSEcCtD
Mirtazapine—Chest pain—Lovastatin—atherosclerosis	0.000257	0.0018	CcSEcCtD
Mirtazapine—Anxiety—Lovastatin—atherosclerosis	0.000256	0.00179	CcSEcCtD
Mirtazapine—Dyspepsia—Rosuvastatin—atherosclerosis	0.000255	0.00179	CcSEcCtD
Mirtazapine—Hypertension—Ezetimibe—atherosclerosis	0.000255	0.00179	CcSEcCtD
Mirtazapine—Flatulence—Niacin—atherosclerosis	0.000255	0.00179	CcSEcCtD
Mirtazapine—Malaise—Simvastatin—atherosclerosis	0.000254	0.00178	CcSEcCtD
Mirtazapine—Tension—Niacin—atherosclerosis	0.000254	0.00178	CcSEcCtD
Mirtazapine—Discomfort—Lovastatin—atherosclerosis	0.000253	0.00177	CcSEcCtD
Mirtazapine—Vertigo—Simvastatin—atherosclerosis	0.000253	0.00177	CcSEcCtD
Mirtazapine—Leukopenia—Simvastatin—atherosclerosis	0.000252	0.00177	CcSEcCtD
Mirtazapine—Chest pain—Ezetimibe—atherosclerosis	0.000252	0.00176	CcSEcCtD
Mirtazapine—Myalgia—Ezetimibe—atherosclerosis	0.000252	0.00176	CcSEcCtD
Mirtazapine—Arthralgia—Ezetimibe—atherosclerosis	0.000252	0.00176	CcSEcCtD
Mirtazapine—Nervousness—Niacin—atherosclerosis	0.000251	0.00176	CcSEcCtD
Mirtazapine—Flatulence—Pravastatin—atherosclerosis	0.000251	0.00176	CcSEcCtD
Mirtazapine—Dry mouth—Lovastatin—atherosclerosis	0.000251	0.00176	CcSEcCtD
Mirtazapine—Tension—Pravastatin—atherosclerosis	0.00025	0.00175	CcSEcCtD
Mirtazapine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00025	0.00175	CcSEcCtD
Mirtazapine—Dysgeusia—Pravastatin—atherosclerosis	0.00025	0.00175	CcSEcCtD
Mirtazapine—Discomfort—Ezetimibe—atherosclerosis	0.000249	0.00174	CcSEcCtD
Mirtazapine—Constipation—Rosuvastatin—atherosclerosis	0.000248	0.00174	CcSEcCtD
Mirtazapine—Pain—Rosuvastatin—atherosclerosis	0.000248	0.00174	CcSEcCtD
Mirtazapine—Confusional state—Lovastatin—atherosclerosis	0.000248	0.00174	CcSEcCtD
Mirtazapine—Nervousness—Pravastatin—atherosclerosis	0.000248	0.00173	CcSEcCtD
Mirtazapine—Dry mouth—Ezetimibe—atherosclerosis	0.000246	0.00172	CcSEcCtD
Mirtazapine—Infection—Lovastatin—atherosclerosis	0.000244	0.00171	CcSEcCtD
Mirtazapine—Confusional state—Ezetimibe—atherosclerosis	0.000243	0.0017	CcSEcCtD
Mirtazapine—HRH1—connective tissue—atherosclerosis	0.000242	0.0149	CbGeAlD
Mirtazapine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000241	0.00169	CcSEcCtD
Mirtazapine—Arthralgia—Simvastatin—atherosclerosis	0.00024	0.00168	CcSEcCtD
Mirtazapine—Chest pain—Simvastatin—atherosclerosis	0.00024	0.00168	CcSEcCtD
Mirtazapine—Myalgia—Simvastatin—atherosclerosis	0.00024	0.00168	CcSEcCtD
Mirtazapine—Infection—Ezetimibe—atherosclerosis	0.00024	0.00168	CcSEcCtD
Mirtazapine—ADRA1A—adipose tissue—atherosclerosis	0.000239	0.0147	CbGeAlD
Mirtazapine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000239	0.00167	CcSEcCtD
Mirtazapine—Anxiety—Simvastatin—atherosclerosis	0.000239	0.00167	CcSEcCtD
Mirtazapine—Tremor—Pravastatin—atherosclerosis	0.000239	0.00167	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000237	0.00166	CcSEcCtD
Mirtazapine—ADRA2A—connective tissue—atherosclerosis	0.000237	0.0146	CbGeAlD
Mirtazapine—Discomfort—Simvastatin—atherosclerosis	0.000237	0.00166	CcSEcCtD
Mirtazapine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000237	0.00166	CcSEcCtD
Mirtazapine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000236	0.00166	CcSEcCtD
Mirtazapine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000236	0.00165	CcSEcCtD
Mirtazapine—Anaemia—Pravastatin—atherosclerosis	0.000236	0.00165	CcSEcCtD
Mirtazapine—Anorexia—Lovastatin—atherosclerosis	0.000234	0.00164	CcSEcCtD
Mirtazapine—Skin disorder—Ezetimibe—atherosclerosis	0.000234	0.00164	CcSEcCtD
Mirtazapine—Vertigo—Niacin—atherosclerosis	0.000233	0.00163	CcSEcCtD
Mirtazapine—Syncope—Niacin—atherosclerosis	0.000232	0.00163	CcSEcCtD
Mirtazapine—Confusional state—Simvastatin—atherosclerosis	0.000232	0.00162	CcSEcCtD
Mirtazapine—Leukopenia—Niacin—atherosclerosis	0.000232	0.00162	CcSEcCtD
Mirtazapine—Urticaria—Rosuvastatin—atherosclerosis	0.000231	0.00161	CcSEcCtD
Mirtazapine—Oedema—Simvastatin—atherosclerosis	0.00023	0.00161	CcSEcCtD
Mirtazapine—Malaise—Pravastatin—atherosclerosis	0.00023	0.00161	CcSEcCtD
Mirtazapine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000229	0.00161	CcSEcCtD
Mirtazapine—Vertigo—Pravastatin—atherosclerosis	0.000229	0.0016	CcSEcCtD
Mirtazapine—Palpitations—Niacin—atherosclerosis	0.000229	0.0016	CcSEcCtD
Mirtazapine—Infection—Simvastatin—atherosclerosis	0.000229	0.0016	CcSEcCtD
Mirtazapine—ADRA2C—adipose tissue—atherosclerosis	0.000228	0.014	CbGeAlD
Mirtazapine—Leukopenia—Pravastatin—atherosclerosis	0.000228	0.0016	CcSEcCtD
Mirtazapine—Loss of consciousness—Niacin—atherosclerosis	0.000227	0.00159	CcSEcCtD
Mirtazapine—Cough—Niacin—atherosclerosis	0.000226	0.00158	CcSEcCtD
Mirtazapine—Thrombocytopenia—Simvastatin—atherosclerosis	0.000225	0.00158	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000224	0.00157	CcSEcCtD
Mirtazapine—Insomnia—Lovastatin—atherosclerosis	0.000222	0.00156	CcSEcCtD
Mirtazapine—Cough—Pravastatin—atherosclerosis	0.000222	0.00156	CcSEcCtD
Mirtazapine—Paraesthesia—Lovastatin—atherosclerosis	0.000221	0.00155	CcSEcCtD
Mirtazapine—Myalgia—Niacin—atherosclerosis	0.00022	0.00154	CcSEcCtD
Mirtazapine—Arthralgia—Niacin—atherosclerosis	0.00022	0.00154	CcSEcCtD
Mirtazapine—Hypertension—Pravastatin—atherosclerosis	0.00022	0.00154	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00022	0.00154	CcSEcCtD
Mirtazapine—Anorexia—Simvastatin—atherosclerosis	0.000219	0.00154	CcSEcCtD
Mirtazapine—Dyspnoea—Lovastatin—atherosclerosis	0.000219	0.00154	CcSEcCtD
Mirtazapine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000219	0.00153	CcSEcCtD
Mirtazapine—Insomnia—Ezetimibe—atherosclerosis	0.000218	0.00153	CcSEcCtD
Mirtazapine—Arthralgia—Pravastatin—atherosclerosis	0.000217	0.00152	CcSEcCtD
Mirtazapine—Chest pain—Pravastatin—atherosclerosis	0.000217	0.00152	CcSEcCtD
Mirtazapine—Myalgia—Pravastatin—atherosclerosis	0.000217	0.00152	CcSEcCtD
Mirtazapine—Paraesthesia—Ezetimibe—atherosclerosis	0.000217	0.00152	CcSEcCtD
Mirtazapine—Dyspepsia—Lovastatin—atherosclerosis	0.000217	0.00152	CcSEcCtD
Mirtazapine—Anxiety—Pravastatin—atherosclerosis	0.000216	0.00151	CcSEcCtD
Mirtazapine—Dry mouth—Niacin—atherosclerosis	0.000216	0.00151	CcSEcCtD
Mirtazapine—Dyspnoea—Ezetimibe—atherosclerosis	0.000215	0.00151	CcSEcCtD
Mirtazapine—Discomfort—Pravastatin—atherosclerosis	0.000214	0.0015	CcSEcCtD
Mirtazapine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000214	0.0015	CcSEcCtD
Mirtazapine—Decreased appetite—Lovastatin—atherosclerosis	0.000214	0.0015	CcSEcCtD
Mirtazapine—CYP2C9—cardiovascular system—atherosclerosis	0.000213	0.0131	CbGeAlD
Mirtazapine—Dyspepsia—Ezetimibe—atherosclerosis	0.000212	0.00149	CcSEcCtD
Mirtazapine—Fatigue—Lovastatin—atherosclerosis	0.000212	0.00148	CcSEcCtD
Mirtazapine—Oedema—Niacin—atherosclerosis	0.000211	0.00148	CcSEcCtD
Mirtazapine—Pain—Lovastatin—atherosclerosis	0.00021	0.00147	CcSEcCtD
Mirtazapine—Constipation—Lovastatin—atherosclerosis	0.00021	0.00147	CcSEcCtD
Mirtazapine—Confusional state—Pravastatin—atherosclerosis	0.00021	0.00147	CcSEcCtD
Mirtazapine—Decreased appetite—Ezetimibe—atherosclerosis	0.00021	0.00147	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00021	0.00147	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000208	0.00146	CcSEcCtD
Mirtazapine—Asthenia—Rosuvastatin—atherosclerosis	0.000208	0.00146	CcSEcCtD
Mirtazapine—Insomnia—Simvastatin—atherosclerosis	0.000208	0.00146	CcSEcCtD
Mirtazapine—Oedema—Pravastatin—atherosclerosis	0.000208	0.00146	CcSEcCtD
Mirtazapine—Fatigue—Ezetimibe—atherosclerosis	0.000208	0.00146	CcSEcCtD
Mirtazapine—Shock—Niacin—atherosclerosis	0.000208	0.00146	CcSEcCtD
Mirtazapine—Infection—Pravastatin—atherosclerosis	0.000207	0.00145	CcSEcCtD
Mirtazapine—Paraesthesia—Simvastatin—atherosclerosis	0.000207	0.00145	CcSEcCtD
Mirtazapine—Constipation—Ezetimibe—atherosclerosis	0.000206	0.00144	CcSEcCtD
Mirtazapine—Pain—Ezetimibe—atherosclerosis	0.000206	0.00144	CcSEcCtD
Mirtazapine—Tachycardia—Niacin—atherosclerosis	0.000206	0.00144	CcSEcCtD
Mirtazapine—Pruritus—Rosuvastatin—atherosclerosis	0.000205	0.00144	CcSEcCtD
Mirtazapine—Skin disorder—Niacin—atherosclerosis	0.000205	0.00144	CcSEcCtD
Mirtazapine—Dyspnoea—Simvastatin—atherosclerosis	0.000205	0.00144	CcSEcCtD
Mirtazapine—Hyperhidrosis—Niacin—atherosclerosis	0.000204	0.00143	CcSEcCtD
Mirtazapine—Thrombocytopenia—Pravastatin—atherosclerosis	0.000204	0.00143	CcSEcCtD
Mirtazapine—Feeling abnormal—Lovastatin—atherosclerosis	0.000203	0.00142	CcSEcCtD
Mirtazapine—Dyspepsia—Simvastatin—atherosclerosis	0.000203	0.00142	CcSEcCtD
Mirtazapine—HTR2A—connective tissue—atherosclerosis	0.000202	0.0124	CbGeAlD
Mirtazapine—Anorexia—Niacin—atherosclerosis	0.000201	0.00141	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000201	0.00141	CcSEcCtD
Mirtazapine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000201	0.00141	CcSEcCtD
Mirtazapine—Decreased appetite—Simvastatin—atherosclerosis	0.0002	0.0014	CcSEcCtD
Mirtazapine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000199	0.00139	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000199	0.00139	CcSEcCtD
Mirtazapine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000199	0.00139	CcSEcCtD
Mirtazapine—Fatigue—Simvastatin—atherosclerosis	0.000198	0.00139	CcSEcCtD
Mirtazapine—Anorexia—Pravastatin—atherosclerosis	0.000198	0.00139	CcSEcCtD
Mirtazapine—Hypotension—Niacin—atherosclerosis	0.000197	0.00138	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000197	0.00138	CcSEcCtD
Mirtazapine—Constipation—Simvastatin—atherosclerosis	0.000197	0.00138	CcSEcCtD
Mirtazapine—Pain—Simvastatin—atherosclerosis	0.000197	0.00138	CcSEcCtD
Mirtazapine—Urticaria—Lovastatin—atherosclerosis	0.000195	0.00137	CcSEcCtD
Mirtazapine—Abdominal pain—Lovastatin—atherosclerosis	0.000194	0.00136	CcSEcCtD
Mirtazapine—Body temperature increased—Lovastatin—atherosclerosis	0.000194	0.00136	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000192	0.00135	CcSEcCtD
Mirtazapine—Dizziness—Rosuvastatin—atherosclerosis	0.000192	0.00134	CcSEcCtD
Mirtazapine—Urticaria—Ezetimibe—atherosclerosis	0.000192	0.00134	CcSEcCtD
Mirtazapine—Insomnia—Niacin—atherosclerosis	0.000191	0.00134	CcSEcCtD
Mirtazapine—Body temperature increased—Ezetimibe—atherosclerosis	0.000191	0.00134	CcSEcCtD
Mirtazapine—Abdominal pain—Ezetimibe—atherosclerosis	0.000191	0.00134	CcSEcCtD
Mirtazapine—Paraesthesia—Niacin—atherosclerosis	0.00019	0.00133	CcSEcCtD
Mirtazapine—Feeling abnormal—Simvastatin—atherosclerosis	0.00019	0.00133	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000189	0.00133	CcSEcCtD
Mirtazapine—Dyspnoea—Niacin—atherosclerosis	0.000188	0.00132	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000188	0.00132	CcSEcCtD
Mirtazapine—Insomnia—Pravastatin—atherosclerosis	0.000188	0.00132	CcSEcCtD
Mirtazapine—Somnolence—Niacin—atherosclerosis	0.000188	0.00131	CcSEcCtD
Mirtazapine—Paraesthesia—Pravastatin—atherosclerosis	0.000187	0.00131	CcSEcCtD
Mirtazapine—Dyspepsia—Niacin—atherosclerosis	0.000186	0.0013	CcSEcCtD
Mirtazapine—Dyspnoea—Pravastatin—atherosclerosis	0.000185	0.0013	CcSEcCtD
Mirtazapine—HRH1—adipose tissue—atherosclerosis	0.000185	0.0114	CbGeAlD
Mirtazapine—Decreased appetite—Niacin—atherosclerosis	0.000184	0.00129	CcSEcCtD
Mirtazapine—Dyspepsia—Pravastatin—atherosclerosis	0.000183	0.00128	CcSEcCtD
Mirtazapine—Rash—Rosuvastatin—atherosclerosis	0.000183	0.00128	CcSEcCtD
Mirtazapine—Dermatitis—Rosuvastatin—atherosclerosis	0.000183	0.00128	CcSEcCtD
Mirtazapine—Urticaria—Simvastatin—atherosclerosis	0.000183	0.00128	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000182	0.00128	CcSEcCtD
Mirtazapine—ADRA2A—adipose tissue—atherosclerosis	0.000182	0.0112	CbGeAlD
Mirtazapine—Body temperature increased—Simvastatin—atherosclerosis	0.000182	0.00127	CcSEcCtD
Mirtazapine—Abdominal pain—Simvastatin—atherosclerosis	0.000182	0.00127	CcSEcCtD
Mirtazapine—Headache—Rosuvastatin—atherosclerosis	0.000182	0.00127	CcSEcCtD
Mirtazapine—Hypersensitivity—Lovastatin—atherosclerosis	0.000181	0.00127	CcSEcCtD
Mirtazapine—Decreased appetite—Pravastatin—atherosclerosis	0.000181	0.00127	CcSEcCtD
Mirtazapine—Pain—Niacin—atherosclerosis	0.000181	0.00126	CcSEcCtD
Mirtazapine—Fatigue—Pravastatin—atherosclerosis	0.000179	0.00126	CcSEcCtD
Mirtazapine—Pain—Pravastatin—atherosclerosis	0.000178	0.00125	CcSEcCtD
Mirtazapine—Constipation—Pravastatin—atherosclerosis	0.000178	0.00125	CcSEcCtD
Mirtazapine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000178	0.00124	CcSEcCtD
Mirtazapine—Asthenia—Lovastatin—atherosclerosis	0.000176	0.00124	CcSEcCtD
Mirtazapine—HTR2A—cardiovascular system—atherosclerosis	0.000176	0.0108	CbGeAlD
Mirtazapine—HTR7—liver—atherosclerosis	0.000174	0.0107	CbGeAlD
Mirtazapine—Pruritus—Lovastatin—atherosclerosis	0.000174	0.00122	CcSEcCtD
Mirtazapine—Asthenia—Ezetimibe—atherosclerosis	0.000173	0.00121	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Niacin—atherosclerosis	0.000173	0.00121	CcSEcCtD
Mirtazapine—Nausea—Rosuvastatin—atherosclerosis	0.000172	0.00121	CcSEcCtD
Mirtazapine—Feeling abnormal—Pravastatin—atherosclerosis	0.000171	0.0012	CcSEcCtD
Mirtazapine—Pruritus—Ezetimibe—atherosclerosis	0.000171	0.0012	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00017	0.00119	CcSEcCtD
Mirtazapine—Hypersensitivity—Simvastatin—atherosclerosis	0.000169	0.00119	CcSEcCtD
Mirtazapine—Diarrhoea—Lovastatin—atherosclerosis	0.000168	0.00118	CcSEcCtD
Mirtazapine—ADRA1A—liver—atherosclerosis	0.000168	0.0103	CbGeAlD
Mirtazapine—Urticaria—Niacin—atherosclerosis	0.000168	0.00117	CcSEcCtD
Mirtazapine—Body temperature increased—Niacin—atherosclerosis	0.000167	0.00117	CcSEcCtD
Mirtazapine—Abdominal pain—Niacin—atherosclerosis	0.000167	0.00117	CcSEcCtD
Mirtazapine—Urticaria—Pravastatin—atherosclerosis	0.000165	0.00116	CcSEcCtD
Mirtazapine—Asthenia—Simvastatin—atherosclerosis	0.000165	0.00116	CcSEcCtD
Mirtazapine—Diarrhoea—Ezetimibe—atherosclerosis	0.000165	0.00116	CcSEcCtD
Mirtazapine—Body temperature increased—Pravastatin—atherosclerosis	0.000164	0.00115	CcSEcCtD
Mirtazapine—Abdominal pain—Pravastatin—atherosclerosis	0.000164	0.00115	CcSEcCtD
Mirtazapine—Pruritus—Simvastatin—atherosclerosis	0.000163	0.00114	CcSEcCtD
Mirtazapine—Dizziness—Lovastatin—atherosclerosis	0.000163	0.00114	CcSEcCtD
Mirtazapine—ADRA2C—liver—atherosclerosis	0.00016	0.00984	CbGeAlD
Mirtazapine—Dizziness—Ezetimibe—atherosclerosis	0.00016	0.00112	CcSEcCtD
Mirtazapine—Diarrhoea—Simvastatin—atherosclerosis	0.000157	0.0011	CcSEcCtD
Mirtazapine—Vomiting—Lovastatin—atherosclerosis	0.000156	0.00109	CcSEcCtD
Mirtazapine—Hypersensitivity—Niacin—atherosclerosis	0.000156	0.00109	CcSEcCtD
Mirtazapine—Rash—Lovastatin—atherosclerosis	0.000155	0.00109	CcSEcCtD
Mirtazapine—Dermatitis—Lovastatin—atherosclerosis	0.000155	0.00108	CcSEcCtD
Mirtazapine—Headache—Lovastatin—atherosclerosis	0.000154	0.00108	CcSEcCtD
Mirtazapine—Vomiting—Ezetimibe—atherosclerosis	0.000153	0.00107	CcSEcCtD
Mirtazapine—Hypersensitivity—Pravastatin—atherosclerosis	0.000153	0.00107	CcSEcCtD
Mirtazapine—Dizziness—Simvastatin—atherosclerosis	0.000152	0.00107	CcSEcCtD
Mirtazapine—Rash—Ezetimibe—atherosclerosis	0.000152	0.00107	CcSEcCtD
Mirtazapine—Dermatitis—Ezetimibe—atherosclerosis	0.000152	0.00106	CcSEcCtD
Mirtazapine—Asthenia—Niacin—atherosclerosis	0.000152	0.00106	CcSEcCtD
Mirtazapine—Headache—Ezetimibe—atherosclerosis	0.000151	0.00106	CcSEcCtD
Mirtazapine—Pruritus—Niacin—atherosclerosis	0.000149	0.00105	CcSEcCtD
Mirtazapine—Asthenia—Pravastatin—atherosclerosis	0.000149	0.00104	CcSEcCtD
Mirtazapine—CYP2C8—liver—atherosclerosis	0.000148	0.00913	CbGeAlD
Mirtazapine—Pruritus—Pravastatin—atherosclerosis	0.000147	0.00103	CcSEcCtD
Mirtazapine—Vomiting—Simvastatin—atherosclerosis	0.000146	0.00102	CcSEcCtD
Mirtazapine—Nausea—Lovastatin—atherosclerosis	0.000146	0.00102	CcSEcCtD
Mirtazapine—Rash—Simvastatin—atherosclerosis	0.000145	0.00102	CcSEcCtD
Mirtazapine—Dermatitis—Simvastatin—atherosclerosis	0.000145	0.00101	CcSEcCtD
Mirtazapine—Diarrhoea—Niacin—atherosclerosis	0.000145	0.00101	CcSEcCtD
Mirtazapine—Headache—Simvastatin—atherosclerosis	0.000144	0.00101	CcSEcCtD
Mirtazapine—Nausea—Ezetimibe—atherosclerosis	0.000143	0.001	CcSEcCtD
Mirtazapine—Diarrhoea—Pravastatin—atherosclerosis	0.000142	0.000996	CcSEcCtD
Mirtazapine—Dizziness—Niacin—atherosclerosis	0.00014	0.000978	CcSEcCtD
Mirtazapine—CYP1A2—liver—atherosclerosis	0.000139	0.00854	CbGeAlD
Mirtazapine—Dizziness—Pravastatin—atherosclerosis	0.000138	0.000963	CcSEcCtD
Mirtazapine—Nausea—Simvastatin—atherosclerosis	0.000137	0.000957	CcSEcCtD
Mirtazapine—Vomiting—Niacin—atherosclerosis	0.000134	0.00094	CcSEcCtD
Mirtazapine—Rash—Niacin—atherosclerosis	0.000133	0.000933	CcSEcCtD
Mirtazapine—Dermatitis—Niacin—atherosclerosis	0.000133	0.000932	CcSEcCtD
Mirtazapine—Headache—Niacin—atherosclerosis	0.000132	0.000927	CcSEcCtD
Mirtazapine—Vomiting—Pravastatin—atherosclerosis	0.000132	0.000926	CcSEcCtD
Mirtazapine—CYP2C9—liver—atherosclerosis	0.000132	0.00811	CbGeAlD
Mirtazapine—Rash—Pravastatin—atherosclerosis	0.000131	0.000918	CcSEcCtD
Mirtazapine—Dermatitis—Pravastatin—atherosclerosis	0.000131	0.000917	CcSEcCtD
Mirtazapine—Headache—Pravastatin—atherosclerosis	0.00013	0.000912	CcSEcCtD
Mirtazapine—Nausea—Niacin—atherosclerosis	0.000125	0.000879	CcSEcCtD
Mirtazapine—Nausea—Pravastatin—atherosclerosis	0.000124	0.000865	CcSEcCtD
Mirtazapine—HTR2A—liver—atherosclerosis	0.000109	0.00668	CbGeAlD
Mirtazapine—CYP3A4—liver—atherosclerosis	0.000101	0.00618	CbGeAlD
Mirtazapine—CYP2D6—liver—atherosclerosis	9.89e-05	0.00608	CbGeAlD
Mirtazapine—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	3.27e-06	2.96e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—CD36—atherosclerosis	3.27e-06	2.96e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—STAT3—atherosclerosis	3.25e-06	2.94e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—MMP9—atherosclerosis	3.25e-06	2.94e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—MAPK3—atherosclerosis	3.24e-06	2.93e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	3.24e-06	2.93e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—CD36—atherosclerosis	3.24e-06	2.93e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—HMGCR—atherosclerosis	3.22e-06	2.91e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—NFKB1—atherosclerosis	3.21e-06	2.91e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	3.2e-06	2.89e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	3.2e-06	2.89e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—TGFB1—atherosclerosis	3.2e-06	2.89e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	3.19e-06	2.89e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—HMOX1—atherosclerosis	3.19e-06	2.88e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	3.19e-06	2.88e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—PIK3CG—atherosclerosis	3.17e-06	2.87e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—INS—atherosclerosis	3.16e-06	2.86e-05	CbGpPWpGaD
Mirtazapine—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	3.16e-06	2.86e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—MAPK8—atherosclerosis	3.16e-06	2.86e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling by GPCR—AKT1—atherosclerosis	3.15e-06	2.85e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—TGFB1—atherosclerosis	3.15e-06	2.85e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	3.13e-06	2.83e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	3.13e-06	2.83e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	3.13e-06	2.83e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	3.11e-06	2.82e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling by GPCR—IL6—atherosclerosis	3.11e-06	2.81e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	3.11e-06	2.81e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—MAPK3—atherosclerosis	3.11e-06	2.81e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—STAT3—atherosclerosis	3.1e-06	2.81e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—MTHFR—atherosclerosis	3.1e-06	2.8e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—NOS3—atherosclerosis	3.1e-06	2.8e-05	CbGpPWpGaD
Mirtazapine—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	3.09e-06	2.8e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—MTHFR—atherosclerosis	3.07e-06	2.78e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—PPARG—atherosclerosis	3.06e-06	2.77e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	3.06e-06	2.77e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—APOB—atherosclerosis	3.05e-06	2.76e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	3.05e-06	2.76e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling by GPCR—IL6—atherosclerosis	3.04e-06	2.75e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—NOS3—atherosclerosis	3.04e-06	2.75e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—PPARA—atherosclerosis	3.04e-06	2.75e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Metabolism—PTGS2—atherosclerosis	3.03e-06	2.74e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	3.03e-06	2.74e-05	CbGpPWpGaD
Mirtazapine—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	3.02e-06	2.73e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—TGFB1—atherosclerosis	3.01e-06	2.73e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—PPARA—atherosclerosis	3.01e-06	2.73e-05	CbGpPWpGaD
Mirtazapine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	3.01e-06	2.72e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—INS—atherosclerosis	3e-06	2.71e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	2.98e-06	2.7e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling by GPCR—IL6—atherosclerosis	2.98e-06	2.69e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—GSTM1—atherosclerosis	2.97e-06	2.69e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	2.97e-06	2.68e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	2.96e-06	2.68e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—MMP9—atherosclerosis	2.96e-06	2.68e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—AGT—atherosclerosis	2.94e-06	2.66e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	2.93e-06	2.65e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	2.93e-06	2.65e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—AGT—atherosclerosis	2.92e-06	2.64e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—VEGFA—atherosclerosis	2.92e-06	2.64e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—LPL—atherosclerosis	2.92e-06	2.64e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	2.9e-06	2.63e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—MMP9—atherosclerosis	2.89e-06	2.62e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—STAT3—atherosclerosis	2.89e-06	2.61e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—APOE—atherosclerosis	2.88e-06	2.61e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	2.88e-06	2.6e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	2.88e-06	2.6e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	2.88e-06	2.6e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	2.87e-06	2.6e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—ABCA1—atherosclerosis	2.87e-06	2.59e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	2.86e-06	2.59e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—APOE—atherosclerosis	2.86e-06	2.59e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—CAV1—atherosclerosis	2.86e-06	2.58e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—APOA1—atherosclerosis	2.85e-06	2.58e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—GPX1—atherosclerosis	2.84e-06	2.57e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—CAV1—atherosclerosis	2.83e-06	2.56e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—MMP9—atherosclerosis	2.83e-06	2.56e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—APOA1—atherosclerosis	2.83e-06	2.56e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	2.82e-06	2.55e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	2.82e-06	2.55e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	2.81e-06	2.54e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	2.8e-06	2.53e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	2.79e-06	2.52e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	2.77e-06	2.51e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—CD36—atherosclerosis	2.77e-06	2.51e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—MAPK3—atherosclerosis	2.76e-06	2.5e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	2.75e-06	2.49e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—ALB—atherosclerosis	2.75e-06	2.49e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—CXCL8—atherosclerosis	2.75e-06	2.49e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	2.75e-06	2.48e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	2.74e-06	2.48e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	2.74e-06	2.48e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	2.73e-06	2.47e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	2.71e-06	2.45e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	2.7e-06	2.45e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—CXCL8—atherosclerosis	2.7e-06	2.44e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—TGFB1—atherosclerosis	2.68e-06	2.42e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	2.66e-06	2.41e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	2.66e-06	2.4e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	2.66e-06	2.4e-05	CbGpPWpGaD
Mirtazapine—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	2.65e-06	2.4e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	2.65e-06	2.39e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—NOS3—atherosclerosis	2.63e-06	2.38e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—STAT3—atherosclerosis	2.63e-06	2.38e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—MTHFR—atherosclerosis	2.62e-06	2.37e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling by GPCR—IL6—atherosclerosis	2.61e-06	2.36e-05	CbGpPWpGaD
Mirtazapine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	2.61e-06	2.36e-05	CbGpPWpGaD
Mirtazapine—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	2.61e-06	2.36e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	2.6e-06	2.35e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	2.6e-06	2.35e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	2.58e-06	2.33e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—PPARA—atherosclerosis	2.58e-06	2.33e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—STAT3—atherosclerosis	2.57e-06	2.33e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	2.57e-06	2.33e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling by GPCR—IL6—atherosclerosis	2.57e-06	2.32e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	2.56e-06	2.31e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	2.54e-06	2.3e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	2.53e-06	2.29e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	2.52e-06	2.28e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—STAT3—atherosclerosis	2.52e-06	2.28e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	2.51e-06	2.27e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—PPARG—atherosclerosis	2.51e-06	2.27e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	2.5e-06	2.26e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—AGT—atherosclerosis	2.49e-06	2.26e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—PPARG—atherosclerosis	2.49e-06	2.25e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—MMP9—atherosclerosis	2.49e-06	2.25e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—INS—atherosclerosis	2.46e-06	2.23e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.46e-06	2.22e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	2.46e-06	2.22e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	2.46e-06	2.22e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	2.46e-06	2.22e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—NFKB1—atherosclerosis	2.46e-06	2.22e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	2.45e-06	2.21e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—APOE—atherosclerosis	2.44e-06	2.21e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—INS—atherosclerosis	2.44e-06	2.21e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—MMP9—atherosclerosis	2.44e-06	2.21e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	2.44e-06	2.21e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	2.44e-06	2.2e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—CAV1—atherosclerosis	2.42e-06	2.19e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.42e-06	2.19e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—MAPK8—atherosclerosis	2.42e-06	2.19e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—APOA1—atherosclerosis	2.42e-06	2.18e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.41e-06	2.18e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling by GPCR—AKT1—atherosclerosis	2.41e-06	2.18e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—IL6—atherosclerosis	2.41e-06	2.18e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—PTGS2—atherosclerosis	2.41e-06	2.18e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.4e-06	2.17e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	2.39e-06	2.17e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.39e-06	2.16e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	2.39e-06	2.16e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.38e-06	2.15e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	2.38e-06	2.15e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.37e-06	2.15e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—IL6—atherosclerosis	2.37e-06	2.15e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.37e-06	2.15e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	2.37e-06	2.14e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.37e-06	2.14e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—APOB—atherosclerosis	2.36e-06	2.13e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	2.34e-06	2.12e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.33e-06	2.11e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	2.33e-06	2.11e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	2.33e-06	2.1e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	2.32e-06	2.1e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.32e-06	2.1e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.29e-06	2.07e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—IL6—atherosclerosis	2.27e-06	2.05e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—ALB—atherosclerosis	2.26e-06	2.04e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	2.26e-06	2.04e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—LPL—atherosclerosis	2.25e-06	2.03e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—ALB—atherosclerosis	2.24e-06	2.03e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—VEGFA—atherosclerosis	2.23e-06	2.02e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	2.22e-06	2.01e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—AKT1—atherosclerosis	2.22e-06	2.01e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—STAT3—atherosclerosis	2.21e-06	2e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	2.21e-06	1.99e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	2.2e-06	1.99e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	2.2e-06	1.99e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—GPX1—atherosclerosis	2.19e-06	1.99e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—VEGFA—atherosclerosis	2.19e-06	1.98e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—AKT1—atherosclerosis	2.19e-06	1.98e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	2.17e-06	1.97e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—STAT3—atherosclerosis	2.17e-06	1.96e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—IL6—atherosclerosis	2.17e-06	1.96e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	2.16e-06	1.96e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—NOS3—atherosclerosis	2.16e-06	1.95e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	2.16e-06	1.95e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	2.15e-06	1.94e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—NOS3—atherosclerosis	2.14e-06	1.94e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CD36—atherosclerosis	2.14e-06	1.93e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	2.13e-06	1.93e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—PPARG—atherosclerosis	2.13e-06	1.92e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—MAPK3—atherosclerosis	2.11e-06	1.91e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—AKT1—atherosclerosis	2.09e-06	1.89e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—INS—atherosclerosis	2.09e-06	1.89e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	2.08e-06	1.88e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.07e-06	1.87e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—TGFB1—atherosclerosis	2.05e-06	1.85e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	2.03e-06	1.84e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.03e-06	1.83e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—IL6—atherosclerosis	2.02e-06	1.82e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	2.02e-06	1.82e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.01e-06	1.82e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—AKT1—atherosclerosis	2e-06	1.81e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	2e-06	1.81e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—PPARA—atherosclerosis	1.99e-06	1.8e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	1.98e-06	1.79e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.98e-06	1.79e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	1.97e-06	1.78e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—PTGS2—atherosclerosis	1.96e-06	1.77e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—AGT—atherosclerosis	1.92e-06	1.74e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—ALB—atherosclerosis	1.91e-06	1.73e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	1.89e-06	1.71e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—APOE—atherosclerosis	1.89e-06	1.71e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Metabolism—AKT1—atherosclerosis	1.88e-06	1.7e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CAV1—atherosclerosis	1.87e-06	1.69e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—APOA1—atherosclerosis	1.86e-06	1.69e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—AKT1—atherosclerosis	1.86e-06	1.68e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—IL6—atherosclerosis	1.84e-06	1.66e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	1.83e-06	1.66e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—NOS3—atherosclerosis	1.83e-06	1.66e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—IL6—atherosclerosis	1.8e-06	1.63e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—IL6—atherosclerosis	1.76e-06	1.59e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—IL6—atherosclerosis	1.75e-06	1.58e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.7e-06	1.54e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—IL6—atherosclerosis	1.7e-06	1.54e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—AKT1—atherosclerosis	1.7e-06	1.53e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.67e-06	1.51e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—AKT1—atherosclerosis	1.66e-06	1.5e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—PPARG—atherosclerosis	1.64e-06	1.49e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.62e-06	1.47e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.61e-06	1.46e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—INS—atherosclerosis	1.61e-06	1.46e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.57e-06	1.42e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—IL6—atherosclerosis	1.54e-06	1.4e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Metabolism—AKT1—atherosclerosis	1.52e-06	1.38e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.52e-06	1.37e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—IL6—atherosclerosis	1.52e-06	1.37e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.49e-06	1.34e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—ALB—atherosclerosis	1.48e-06	1.34e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—AKT1—atherosclerosis	1.42e-06	1.29e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—NOS3—atherosclerosis	1.41e-06	1.28e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.4e-06	1.27e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.4e-06	1.26e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.38e-06	1.25e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.37e-06	1.24e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.29e-06	1.17e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	1.27e-06	1.15e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—AKT1—atherosclerosis	1.21e-06	1.09e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—AKT1—atherosclerosis	9.93e-07	8.98e-06	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—AKT1—atherosclerosis	9.85e-07	8.91e-06	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—AKT1—atherosclerosis	8.42e-07	7.61e-06	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—AKT1—atherosclerosis	6.49e-07	5.87e-06	CbGpPWpGaD
